Abstract: Disclosed are to bifunctional compounds that target PRMT5 for degradation, compositions, and methods for treating diseases or conditions mediated by aberrant arginine methyltransferase 5 (PRMT5) activity.

Abstract: An electronic device may have a camera. The camera may capture still and moving images. A camera status indicator may be included in the electronic device. The camera status indicator may emit light to indicate when the camera is in use capturing video or other images. The camera status indicator may have multiple light-emitting devices such as light-emitting diodes or lasers. The light-emitting devices may have different colors. Clear encapsulant may cover the light-emitting devices. A white polymer wall or other light recycling structure may run along an outer peripheral edge of the encapsulant. A light diffusing coating layer may coat an outer surface of the clear encapsulant. Light reflections from the status indicator may be reduced in captured images.

Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one component of the bifunctional compound is a binder of an E3 ubiquitin ligase (e.g., lenalidomide, thalidomide) and another component of the compound is a binder of the target protein DOT1L in a subject.

Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.

Abstract: To enable a display to display different content to different viewers, a display may include a time-sequential directional backlight unit. The backlight unit may emit light in different directions in different configurations. In a first state, the backlight unit emits light at maximum brightness in a first direction. In a second state, the backlight unit emits light at maximum brightness in a second direction that is different than the first direction. The backlight unit may repeatedly and rapidly switch between the different states. The first direction may be towards a first viewer whereas the second direction may be towards a second, different viewer. Therefore, each viewer receives backlight in one of the configurations and does not receive backlight in the other configuration. In synchronization with the backlight unit, the liquid crystal display panel may repeatedly switch between displaying content for the first viewer and displaying content for the second viewer.

Abstract: Disclosed herein are compounds that target SMARCA2, SMARCA4 or BRM, causing their degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes (LEDs) on a printed circuit board. The display may have a notch to accommodate an input-output component. Reflective layers may be included in the notch. The backlight may include a color conversion layer with a property that varies as a function of position. The light-emitting diodes may be covered by a slab of encapsulant with recesses in an upper surface.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes (LEDs) on a printed circuit board. The display may have a notch to accommodate an input-output component. Reflective layers may be included in the notch. The backlight may include a color conversion layer with a property that varies as a function of position. The light-emitting diodes may be covered by a slab of encapsulant with recesses in an upper surface.

Abstract: An electronic device may be provided with a display. The display may be overlapped by an antiglare film. The antiglare film may have a rough surface to diffuse incident light, thereby reducing glare. Additionally, the antiglare film may have a smooth portion that forms a transparent window and allows light to pass through undiffused. The electronic device may include a light-based component, such as a camera, that receives undiffused light through the transparent window. By overlapping the light-based component with the transparent window, the light-based component may receive the light in an unimpeded manner, thereby making more accurate measurements of the light. The display may have one or more display layers, such as opaque masking layers or polarizers, with openings that are aligned with the transparent window. The light-based component may receive the light through these openings so that the light is not absorbed or polarized before reaching the component.

Abstract: Embodiments described herein generally take the form of an electronic device including a primary and secondary display; at least the secondary display is force-sensitive and further has its force-sensing circuitry in-plane with the display. The secondary display and force-sensing circuitry may be encapsulated between two glass layers that are bonded to one another by a frit. In some embodiments the force-sensing circuitry is formed from, or constitutes part of, the frit.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes on a printed circuit board. The backlight unit may include first, second, and third light spreading layers formed over the array of light-emitting diodes. A color conversion layer may be formed over the first, second, and third light spreading layers. First and second brightness enhancement films may be formed over the color conversion layer.

Abstract: A stent device with skirt folds and a processing method thereof, a skirt folding method, and a heart valve. The stent device comprises a stent (1, 105) and a flexible skirt (2, 107), the skirt (2, 107) having an expanded state, in which the skirt is axially extended and surrounds the stent (1, 105) before release thereof, and a folded state, in which the skirt is driven by the deformation caused when the stent (1 , 105) is released, collapses and folds axially along the released stent (1, 105) so as to form an annular peripheral leakage-blocking portion. The peripheral leakage prevention technology enables an interventional stent to fit to the inner wall of a vessel more snugly, such that the stent does not easily move and is more stable, thereby being suitable for more people, reducing additional risks of surgery and preventing complications such as peripheral leakage and thrombus.

Abstract: An electronic device such as a voice-controlled speaker device may have a housing. A speaker and other input-output components and control circuitry may be mounted within the housing. Light-emitting components may emit light that passes through a curved upper top cap portion or other housing structure. The light-emitting components may be interconnected using a flex circuit on a curved substrate or may be mounted on a planar circuit board. A subset of the light-emitting components may be rotated to improve color balance. Optical structures such as light guides, lens, microlenses, and/or a diffuser layer may be disposed over the light-emitting components to promote light mixing, to reduce hotspots, and to improve contrast on the top cap. The diffuser layer may be suspended using a support structure having baffle members to constraint the angular spread of the emitted light. Illuminated or persistently visible glyphs may be displayed in or near the top cap portion.

Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes on a printed circuit board. The backlight unit may include first, second, and third light spreading layers formed over the array of light-emitting diodes. A color conversion layer may be formed over the first, second, and third light spreading layers. First and second brightness enhancement films may be formed over the color conversion layer.

Abstract: Disclosed herein are compounds that target SMARCA2 and SMARCA4, causing their degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes (LEDs) on a printed circuit board. The display may have a notch to accommodate an input-output component. Reflective layers may be included in the notch. The backlight may include a color conversion layer with a property that varies as a function of position. The light-emitting diodes may be covered by a slab of encapsulant with recesses in an upper surface.

Abstract: Provided herein are compounds that inhibit histone lysine demethylase (KDM) and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and methods of treating or preventing diseases (e.g., proliferative diseases, e.g., cancer). In certain embodiments, the compounds described herein are represented by formulas (I) and (II).

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes on a printed circuit board. The backlight unit may include first, second, and third light spreading layers formed over the array of light-emitting diodes. A color conversion layer may be formed over the first, second, and third light spreading layers. First and second brightness enhancement films may be formed over the color conversion layer.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes on a printed circuit board. The backlight unit may include first, second, and third light spreading layers formed over the array of light-emitting diodes. A color conversion layer may be formed over the first, second, and third light spreading layers. First and second brightness enhancement films may be formed over the color conversion layer.